

From: [5.1.2e] [5.1.2e] [5.1.2e]
Importance: Normal
Subject: IMPRINT webinar COVID 19
Start Date/Time: Wed 3/10/2021 2:00:00 PM
End Date/Time: Wed 3/10/2021 3:30:00 PM

Je bent geregistreerd

Dear IMPRINT members,

We would like to remind you about the upcoming IMPRINT webinar on the impact of COVID-19 on neonates and the prevention of COVID-19 through vaccination taking place on **11 March at 15:00-16:30 GMT.**

We have invited [5.1.2e], Professor of Paediatric Infectious Diseases at St George's, University of London, and [5.1.2e] Reader in Neonatal Medicine at Imperial College London. [5.1.2e] will present the **current status of COVID-19 vaccines**, [5.1.2e] will discuss the **impact of COVID-19 on the health of newborns**. Please find more details on the presentations below.

The 20-minute presentations will each be followed by a Q&A session with speakers and audience that are moderated by our Network [5.1.2e] from the London School of Hygiene & Tropical Medicine and [5.1.2e] from the University of Southampton.

For **registration**, please follow this link: https://lshtm.zoom.us/webinar/register/WN_K7z7D9oSQZSST1CA-QNtTg

Presentations

COVID-19: Impact on the health of newborns

[5.1.2e] Imperial College London

Babies differ from older children with regard to their exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). I will describe the incidence, characteristics, transmission, and outcomes of SARS-CoV-2 infection in neonates who received inpatient hospital care in the UK from a prospective population-based cohort study. Neonatal SARS-CoV-2 infection is uncommon in babies admitted to hospital. Infection with neonatal admission following birth to a mother with perinatal SARS-CoV-2 infection was unlikely, and possible vertical transmission rare, supporting international guidance to avoid separation of mother and baby.

COVID-19 vaccines: Current status

Prof. [5.1.2e] St George's, University of London

It was clear at an early stage that the rapid development, distribution and administration of a vaccine to the global population would be the most effective approach to suppress the SARS-CoV-2 pandemic. The first vaccine to be given to humans was the Moderna RNA vaccine which entered its Phase I trial an astonishing 63 days after sequence selection. This candidate represents a new vaccine platform technology and, although more traditional platforms are being employed, the use of new technologies, for which there are no previously licensed examples, is a particular feature of the COVID-19 vaccine field. A number of trials have recently reported efficacy data.


Best wishes,

5.1.2e

On behalf of the IMPRINT Management Board

5.1.2e

IMPRINT network



LINQ management GmbH, Friedbergstr. 35, 14057 Berlin, Germany

Phone: 5.1.2e

<http://www.linq-management.com/>

<http://www.imprint-network.co.uk/>

Twitter: @IMPRINT_network